🇺🇸 Meropenem intravenous in United States

10 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 23 April 2025 – 23 April 2026
• Total reports: 10

Most-reported reactions

1. Alanine Aminotransferase Increased — 1 report (10%)
2. Aspartate Aminotransferase Increased — 1 report (10%)
3. Blood Bilirubin Increased — 1 report (10%)
4. Blood Calcium Decreased — 1 report (10%)
5. Blood Culture Positive — 1 report (10%)
6. Blood Sodium Decreased — 1 report (10%)
7. Colitis — 1 report (10%)
8. Endocarditis — 1 report (10%)
9. Enterococcal Bacteraemia — 1 report (10%)
10. Fluid Overload — 1 report (10%)

Source database →

Frequently asked questions

Is Meropenem intravenous approved in United States?

Meropenem intravenous does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Meropenem intravenous in United States?

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla is the originator. The local marketing authorisation holder may differ — check the official source linked above.